Nine companies listed in the FDA Calendar with 4Q biotech binary events released catalyst related material during the last trading week. On the press release menu were ARDM, BLUE, CERC, CYTR, FOLD, HTBX, NOVN, NVLS and REPH.
Two of the nine companies (BLUE and NOVN) saw their shares react positively to their respective news, while shares of REPH initially saw favor from investors before finishing the week in the red. The remaining six companies saw their shares close down for the week, some more significantly than others, with ARDM, CERC, FOLD and HTBX the major decliners.
Two other companies with 4Q binary events gave updated guidance. Advanced Accelerator Application SA (NASDAQ:AAAP) noted that its PDUFA date for Lutathera is likely to be delayed, while Phase 3 data for Inotek Pharmaceuticals Corp (NASDAQ:ITEK), previously scheduled for 4Q 2016, are now due in early January 2017.
How does this leave the catalyst map for the final four trading weeks of 2016?
We still have 30+ key biotech catalysts on the table of which ten are highlighted below.
A caveat regarding one of the catalysts. Repros Therapeutics Inc. (Nasdaq:RPRX) will attend as a sponsor at the Bone, Reproductive and Urologic Drugs Advisory Committee Meeting on December 6, 2016 where clinical trial design features, including acceptable endpoints for secondary hypogonadism will be discussed. It should be noted that the Advisory Committee will not be meeting to give an approval opinion, rather the company will only be attending as a sponsor. However, shares might still garner some attention from traders leading up to and on the day of the event.
Ten Upcoming Biotech Catalysts due for December, 2016.